| Literature DB >> 32660224 |
Ashraf I Khasawneh1, Nisreen Himsawi1, Jumana Abu-Raideh1, Muna A Salameh2, Mohammad Al-Tamimi1, Sameer Al Haj Mahmoud2, Tareq Saleh1.
Abstract
Background: Biofilm formation in Staphylococcus aureus is a major virulence factor. Both methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA) are common causes of community- and hospital-acquired infections and are associated with biofilm formation. The status of biofilm-forming genes has not been explored in Jordanian nasal carriers of S. aureus. This study investigates antibiotic resistance patterns and the prevalence of biofilm-forming genes between MSSA and MRSA in two distinct populations in Jordan.Entities:
Keywords: Biofilms; Methicillin-resistant Staphylococcus aureus; Methicillin-sensitive Staphylococcus aureus
Mesh:
Substances:
Year: 2020 PMID: 32660224 PMCID: PMC7601545 DOI: 10.29252/ibj.24.6.381
Source DB: PubMed Journal: Iran Biomed J ISSN: 1028-852X
Association of demographic and clinical characteristics with MRSA and MSSA colonization among Prince Hamza Hospital participants
|
|
|
|
| ||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| ||
|
| 23 (11.4) | 1 (4.3) | 0.801 | 1 (4.3) | 0.754 | ||
|
| 82 (40.6) | 4 (4.9) | 0.769 | 0.828 | 6 (7.3) | 0.793 | 0.868 |
|
| 69 (34.2) | 6 (8.7) | 0.236 | 6 (8.7) | 0.694 | ||
|
| 65 (32.2) | 4 (6.2) | 0.760 | 1.218 | 4 (6.2) | 0.522 | 0.683 |
|
| 137 (67.8) | 7 (7.1) | 0.760 | 0.821 | 10 (7.3) | 0.635 | 0.774 |
|
| 118 (58.4) | 8 (6.8) | 0.322 | 1.964 | 10 (8.5) | 0.730 | 1.204 |
|
| 95 (47) | 8 (8.4) | 0.079 | 3.188 | 8 (8.4) | 0.804 | 1.138 |
|
| 98 (48.5) | 6 (6.1) | 0.681 | 1.291 | 6 (6.1) | 0.358 | 0.613 |
|
| 17 (8.4) | 2 (11.8) | 0.230 | 2.607 | 2 (11.8) | 0.540 | 1.629 |
Association of demographic and clinical characteristics with MRSA and MSSA colonization among medical student participants
|
|
|
|
| |||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |||
|
| 290 (100) | 9 (3.1) | 0.855 | 21 (7.2) | 0.026 | |||
|
| 179 (61.7) | 5 (2.8) | 0.699 | 0.769 | 13 (7.3) |
| 1.008 | |
|
| 80 (27.6) | 0 (0.0) | 0.152 | 2 (2.5) |
| |||
|
| 68 (23.4) | 2 (2.9) | 0.930 | 0.931 | 4 (5.9) | 0.621 | 0.754 | |
|
| 103 (35.5) | 4 (3.9) | 0.570 | 1.471 | 16 (15.5) |
|
| |
|
| 75 (25.9) | 1 (1.3) | 0.354 | 0.384 | 5 (6.7) | 0.971 | 0.981 | |
|
| 64 (22.0) | 2 (3.1) | 0.950 | 1.052 | 3 (4.7) | 0.410 | 0.593 | |
|
| 18 (6.2) | 2 (11.1) | 0.034 | 5.067 | 1 (5.6) | 0.824 | 0.791 | |
|
| 24 (8.3) | 0 (0.0) | 0.750 | 0.711 | 3 (12.5) | 0.263 | 2.075 | |
|
| 24 (8.3) | 1 (2.3) | 0.084 | 5.729 | 1 (2.3) | 0.178 | 0.270 | |
Fig. 1Frequency of biofilm formation among MSSA and MRSA isolates
Antibiotic susceptibility pattern among MSSA and MRSA isolates in the biofilm-forming species
|
|
|
| |||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
|
|
| |
| Vancomycin | 4 (11.4) | 28 (80.0) | 3 (8.6) | 35 (100) | 0 | 18 (81.8) | 4 (18.2) | 22 (100) | 0 |
| Cefoxitin | 3 (8.6) | 25 (71.4) | 1 (2.9) | 29 (82.9) | 6 (17.1) | 6 (27.3) | 1 (4.5) | 7 (31.8) | 15 (68.2) |
| Benzyl penicillin | 0 | 4 (11.4) | 0 | 4 (11.4) | 31 (88.6) | 0 | 0 | 0 | 22 (100) |
| Oxacillin | 4 (11.4) | 27 (77.1) | 2 (5.6) | 33 (94.4) | 2 (5.6) | 0 | 0 | 0 | 22 (100) |
| Imipenem | 4 (11.4) | 27 (77.1) | 3 (8.6) | 34 (97.1) | 1 (2.9) | 3 (13.6) | 1 (4.5) | 4 (18.2) | 18 (81.8) |
| Tetracycline | 4 (11.4) | 25 (71.4) | 3 (8.6) | 32 (91.4) | 3 (8.6) | 12 (54.6) | 3 (13.6) | 15 (68.2) | 7 (31.8) |
| Erythromycin | 4 (11.4) | 20 (57.1) | 2 (5.6) | 26 (74.3) | 9 (25.7) | 11 (50) | 1 (4.5) | 12 (54.6) | 10 (45.4) |
| Clindamycin | 4 (11.4) | 22 (62.9) | 3 (8.6) | 29 (82.9) | 6 (17.1) | 11 (50) | 1 (4.5) | 12 (54.6) | 10 (45.4) |
| Ciprofloxacin | 4 (11.4) | 28 (80.0) | 2 (5.6) | 34 (97.1) | 1 (2.9) | 18 (81.8) | 4 (18.2) | 22 (100) | 0 |
| Trimethoprim-Sulfamethoxazole | 4 (11.4) | 28 (80) | 2 (5.6) | 34 (97.1) | 1 (2.9) | 14 (63.6) | 3 (13.6) | 17 (77.3) | 5 (22.7) |
| Gentamycin | 4 (11.4) | 28 (80) | 3 (8.6) | 35 (100) | 0 | 18 (81.8) | 3 (13.6) | 21 (95.5) | 1 (4.5) |
| Tobramycin | 4 (11.4) | 28 (80) | 3 (8.6) | 35 (100) | 0 | 18 (81.8) | 3 (13.6) | 21 (95.5) | 1 (4.5) |
| Fusidic acid | 4 (11.4) | 28 (80) | 3 (8.6) | 35 (100) | 0 | 18 (81.8) | 3 (13.6) | 21 (95.5) | 1 (4.5) |
| Rifampicin | 4 (11.4) | 28 (80) | 3 (8.6) | 35 (100) | 0 | 18 (81.8) | 3 (13.6) | 21 (95.5) | 1 (4.5) |
S, sensitive; R, resistant
Antibiotic resistance pattern among students and patients in MRSA and MSSA nasal isolates
|
|
|
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |||||||
|
|
|
|
|
|
|
|
|
|
| |||
| Cefoxitin | 7 (31.8) | 8 (36.4) | 0.616 | 5 (14.3) | 1(2.9) | 0.209 | 15 (68.2) | 0.001 | 6 (17.1) | 0.001 | ||
| Benzylpenicillin | 10 (45.5) | 12 (54.5) | NA | 20 (57.1) | 11 (31.4) | 0.165 | 22 (100) | 0.100 | 31 (88.6) | 0.10 | ||
| Oxacillin | 10 (45.5) | 12 (54.5) | NA | 2 (5.7) | 0 (0) | 0.353 | 22 (100) | 0.001 | 2 (5.7) | 0.001 | ||
| Imipenem | 8 (36.4) | 10 (45.5) | 0.632 | 0 (0) | 1 (2.9) | 0.400 | 18 (81.8) | 0.001 | 1 (2.9) | 0.001 | ||
| Tetracycline | 3 (13.6) | 4 (18.2) | 0.616 | 0 (0) | 3 (8.6) | 0.056 | 7 (31.8) | 0.025 | 3 (8.6) | 0.025 | ||
| Erythromycin | 3 (13.6) | 7 (31.8) | 0.185 | 6 (17.1) | 3 (8.6) | 0.474 | 10 (45.5) | 0.124 | 9 (25.7) | 0.124 | ||
| Clindamycin | 3 (13.6) | 7 (31.8) | 0.185 | 3 (8.6) | 3 (8.6) | 0.456 | 10 (45.5) | 0.021 | 6 (17.1) | 0.021 | ||
| Ciprofloxacin | 0 (0) | 0 (0) | NA | 1 (2.9) | 0 (0) | 0.600 | 0 (0) | 0.424 | 1 (2.9) | 0.424 | ||
| Trimethoprim- Sulfamethoxazole | 1 (4.5) | 4 (18.2) | 0.218 | 1 (2.9) | 0 (0) | 0.600 | 5 (27.7) | 0.027 | 1 (2.9) | 0.017 | ||
| Gentamycin | 0 (0) | 1 (4.5) | 0.545 | 0 (0) | 0 (0) | NA | 1 (4.5) | 0.203 | 0 (0) | 0.203 | ||
| Tobramycin | 0 (0) | 1 (4.5) | 0.545 | 0 (0) | 0 (0) | NA | 1 (4.5) | 0.203 | 0 (0) | 0.203 | ||
| Fusidic acid | 0 (0) | 1 (4.5) | 0.545 | 0 (0) | 0 (0) | 1 (4.5) | 0.203 | 0.203 | ||||
| Rifampicin | 0 (0) | 1 (4.5) | 0.545 | 0 (0) | 0 (0) | 1 (4.5) | 0.203 | 0.203 | ||||
Fig. 2Multiplex PCR amplification products by agarose gel electrophoresis for the ica and MSCRAMMs-encoding genes. L, DNA molecular size marker (50 bp ladder); N, negative control; lanes 1-13, participants samples; P, positive control
Comparison of the frequency of the biofilm-forming genes between MSSA and MRSA isolates
|
|
|
|
| ||
|---|---|---|---|---|---|
|
|
|
|
| ||
|
| 8 (22.9) | 27 (77.1) | 3 (13.6) | 19 (86.4) | 0.390 |
|
| 1 (2.9) | 34 (97.1) | 0 (0) | 22 (100) | 0.424 |
|
| 1 (2.9) | 34 (97.1) | 0 (0) | 22 (100) | 0.424 |
|
| 2 (5.7) | 33 (94.3) | 0 (0) | 22 (100) | 0.254 |
|
| 10 (28.6) | 25 (71.4) | 4 (18.2) | 18 (81.8) | 0.375 |
|
| 5 (14.3) | 30 (85.7) | 2 (9.1) | 20 (90.9) | 0.561 |
|
| 4 (11.4) | 31 (88.6) | 2 (9.1) | 20 (90.9) | 0.780 |
|
| 0 (0) | 35 (100) | 0 (0) | 22 (100) | NA |
|
| 23 (65.7) | 12 (34.3) | 13 (59.1) | 9 (40.9) | 0.614 |
|
| 2 (5.7) | 33 (94.3) | 0 (0) | 22 (100) | 0.254 |
|
| 3 (8.6) | 32 (91.4) | 1 (4.5) | 21 (95.5) | 0.562 |
|
| 9 (25.7) | 26 (74.3) | 3 (13.6) | 19 (86.4) | 0.276 |
Comparison of the frequency of MRSA and MSSA isolates and percentages of positive biofilm-forming genes between students and patients
|
|
|
|
|
|
|---|---|---|---|---|
| MRSA | 10 (32.3) | 12 (46.2) | 1.152 | 0.283 |
| MSSA | 21(67.7) | 14 (53.8) | 1.152 | 0.283 |
|
| 26 (83.9) | 20 (76.9) | 0.438 | 0.508 |
|
| 30 (96.8) | 25 (96.2) | 0.016 | 0.899 |
|
| 31 (100.0) | 25 (96.2) | 1.214 | 0.271 |
|
| 31 (100.0) | 25 (96.2) | 1.214 | 0.271 |
|
| 22 (71.0) | 21 (80.8) | 0.733 | 0.392 |
|
| 27 (87.1) | 18 (69.2) | 2.716 | 0.099 |
|
| 26 (83.9) | 23 (88.5) | 0.247 | 0.619 |
|
| 11 (35.5) | 10 (38.5) | 0.054 | 0.816 |
|
| 30 (96.8) | 25 (96.2) | 0.016 | 0.899 |
|
| 3 (9.7) | 3 (11.5) | 0.052 | 0.820 |
|
| 15 (48.4) | 10 (38.5) | 0.566 | 0.452 |
|
| 31 (100) | 26 (100) | NA | NA |
| Total | 31 (54.4) | 26 (45.6) |